Tech Company Financing Transactions
Ray Therapeutics Funding Round
Ray Therapeutics, operating out of San Diego, secured $100 million from Novo Holdings, 4BIO Capital and Deerfield Management Company.
Transaction Overview
Company Name
Announced On
5/16/2023
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series A
Investors
Novo Holdings (Lead Investor)
4BIO Capital (Dmitry Kuzmin)
Proceeds Purpose
The company intends to use the funds to advance multiple programs targeting blinding diseases of the eye through clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3625 Dudley St.
San Diego, CA 92106
USA
San Diego, CA 92106
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Paul Bresge
Chief Operating Officer
Andrew Howard
VP - Manufacturing
Crawford Brown
VP - Regulatory Affairs
Kathrin Schalper
Browse more venture capital transactions:
Prev: 5/16/2023: OneDay venture capital transaction
Next: 5/16/2023: Metaphore Biotechnologies venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs